Redeye thinks that Lagercrantz reported a solid quarter despite a drop in organic sales. There was no major surprises which is a quality sign. Lagercrantz have ramped up its acquisition capabilities in recent years and have clearly capitalized on this. We increase our fair value and believe the prospects for continued good profit growth in line with the financial goals are high.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/